KJKaren Chandler Johnson

Karen Chandler Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Karen Chandler Johnson has a total of 546 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-term change in body composition following intentional weight loss and its effect on physical function

    by Kacey Chae, Xiaoyan Leng, Rebecca H. Neiberg, George A. Bray, Karen C. Johnson, James O. Hill, John M. Jakicic, Ariana M. Chao, Kristen M. Beavers, Henry J. Pownall, et al.

    Background/Objectives: A concern with intentional weight loss among middle-aged and older adults with obesity and type 2 diabetes mellitus (T2DM) is the loss of lean mass, which may lead to declining physical function. However, the association between changes in body composition with intentional weight loss and physical function over the long-term is unknown. Thus, we examined the association between changes in body composition and physical function 8 years following an intensive lifestyle intervention (ILI). Subjects/Methods: We conducted a secondary analysis of participants at the Baton Rouge site within the Look AHEAD study. Participants (n = 220) were middle-aged and older adults with overweight/obesity and T2DM randomized to an ILI or diabetes support and education (DSE). Body composition was measured by dual-energy X-ray absorptiometry at baseline and Year 8. Physical performance (expanded Short Physical Performance Battery [SPPB exp ], 20- and 400-m walk) and strength (grip and knee extensor) were assessed at Year 8. Results: Percent change (mean ± SD) from baseline in weight, fat and lean mass over 8 years were −4.0 ± 7.3%, 0.2 ± 12.5% and −6.5 ± 5.3% in ILI and −3.0 ± 9.7%, 1.2 ± 17.1% and −5.8 ± 6.6% in DSE, respectively. ILI had better SPPB exp scores and faster gait speed than DSE at 8-year follow-up (p < 0.05). Increases in fat mass were associated with worse SPPB exp scores in ILI and DSE (p = 0.03) and with slower gait speed in DSE (p = 0.01). Decreases in lean mass were associated with weaker grip strength in ILI (p = 0.04) and knee extensor strength in ILI and DSE (p < 0.05). There were no significant interactions by intervention group. Conclusions: Although the overall intervention effect on physical function was positive, increases in fat mass were associated with poorer physical performance while lean mass loss was associated with weaker strength 8 years post-randomization. Findings highlight the importance of minimizing fat mass gain/regain and loss of lean mass during intentional weight loss.


  • Open Access

    Associations of modifiable lifestyle and clinical factors with cognitive function in adults with type 2 diabetes

    by Anahita Golchin, Karen C. Johnson, Denise K. Houston, Jose A. Luchsinger, Kristen M. Beavers, Alain G. Bertoni, Haiying Chen, Lynne Wagenknecht, Mark A. Espeland


  • Open Access

    Comparative Effectiveness of Metformin Versus Sulfonylureas on Exceptional Longevity in Women With Type 2 Diabetes: Target Trial Emulation

    by Aladdin H Shadyab, Mark A Espeland, Andrew O Odegaard, JoAnn E Manson, Bernhard Haring, Karen C Johnson, Zhao Chen, Bowei Zhang, Andrea Z LaCroix

    Background: The association of metformin with mortality has been mixed, and no prior study has determined whether metformin initiation is associated with exceptional longevity, defined as survival to ages 90 and older. Methods: We performed a new-user, active comparator cohort study using the target trial emulation framework among the Women’s Health Initiative cohort to determine whether metformin versus sulfonylurea initiation was associated with exceptional longevity (survival to age 90). We identified participants ≥60 years with incident type 2 diabetes and no history of hypoglycemic agents or insulin prior to treatment initiation to perform intention-to-treat analyses. We used 1:1 propensity score matching on demographic characteristics, lifestyle behaviors, diabetes duration, comorbidities (hypertension, cardiovascular disease, chronic obstructive pulmonary disease, and cancer), body mass index, and concomitant medications to balance treatment groups on key confounders. Results: Among 438 propensity score-matched women with type 2 diabetes, the incidence rate of death before age 90 per 100 person-years in women initiating metformin monotherapy was 3.7 (95% CI: 3.1–4.4) compared with 5.0 (95% CI: 4.2–5.8) for sulfonylurea monotherapy. The adjusted risk of death before age 90 was 30% lower for initiation of metformin monotherapy versus sulfonylurea monotherapy (hazard ratio, 0.70; 95% CI: 0.56–0.88). Conclusions: In this first target trial emulation of metformin and exceptional longevity, we found that metformin initiation increased exceptional longevity compared with sulfonylurea initiation among women with type 2 diabetes. Because this comparison was not made to placebo in a randomized controlled trial and given the observational design with potential for residual confounding, causality cannot be inferred.


  • Open Access

    Associations between decreases in adiposity and reductions in HbA1c and insulin use in the Look AHEAD cohort

    by Rebecca Palmer, Rebecca H. Neiberg, Kristen M. Beavers, Steven E. Kahn, Denise K. Houston, Lynne Wagenknecht, Karen C. Johnson, Henry J. Pownall, Mark A. Espeland, For the Action for Health in Diabetes (Look AHEAD) Aging Study Group

    Objective: The objective of this study was to elucidate associations between adiposity reduction and changes in HbA1c and insulin use among adults with type 2 diabetes and overweight or obesity.Methods: Changes in BMI, waist circumference, and total percent fat mass were obtained over 8 years among 1316 individuals (aged 45–76 years) enrolled in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss. Generalized linear models were used to assess relationships between 5% decreases in adiposity measures with glycated hemoglobin (HbA1c) and insulin use over time.Results: A 5% reduction in total percent fat was associated with 0.15% (95% CI: 0.12%–0.18%) lower mean HbA1c. Similarly, 5% reductions in waist circumference and BMI were also associated with slightly lower mean HbA1c: 0.16% (95% CI: 0.13%–0.19%) and 0.13% (95% CI: 0.11%–0.16%), respectively. These reductions were associated with lower odds of insulin use over time, ranging from 21% lower odds for a 5% reduction in percent body fat to 32% lower odds for 5% reductions in waist circumference and BMI. Associations were evident across subgroups defined by sex, diabetes duration, obesity status, and intervention assignment.Conclusions: Reductions in adiposity are associated with stabilized and slightly lower HbA1c and a marked reduction in the need for insulin therapy. These benefits generalize across clinical subgroups.


  • A randomized pilot trial of two forms of behavioral economics intervention to improve engagement in buprenorphine-naloxone treatment among patients with opioid use disorder

    by Karen J. Derefinko, Fridtjof Thomas, Samuel C. Peter, James G. Murphy, Katie Witkiewitz, Ron Cowan, Matt Harris, Sarah Hand, Karen C. Johnson


  • Estrogen Plus Progestin and Colorectal Cancer: Long-Term Findings From the Women's Health Initiative Randomized Clinical Trial

    by Rowan T. Chlebowski, Aaron K. Aragaki, Kathy Pan, Juhua Luo, Thomas E. Rohan, Karen C. Johnson, Jean Wactawski-Wende, Su Yon Jung, Qian Xiao, Sayeh Lavasani, et al.

    Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We report long-term colorectal cancer findings from the Women's Health Initiative trial where 16,608 postmenopausal women with a uterus were randomly assigned to daily conjugated equine estrogen (CEE) 0.625 mg, plus medroxyprogesterone acetate (MPA) 2.5 mg, or placebo. When intervention ended after 5.6 years, although there were 44% fewer colorectal cancers in the intervention group (43 v 72, P = .003), the cancers were more commonly lymph node–positive (59.0% v 29.4%, P = .003). Now after cumulative 24-year follow-up, with 431 colorectal cancers, CEE plus MPA no longer influenced colorectal cancer incidence (215 [0.15, annualized rate %] v 216 [0.15], hazard ratio [HR], 0.95 [95% CI, 0.79 to 1.15]). Although not statistically significant, there were more colorectal cancer deaths with CEE plus MPA (87 [0.049] v 69 [0.041] deaths, HR, 1.20 [95% CI, 0.87 to 1.65], P = .26). Vaginal bleeding (54.1% v 5.2% at 6 months) and breast changes were more frequent in the intervention group. After adjusting for postrandomization vaginal bleeding and breast changes, bowel examinations were significantly delayed in intervention group participants ( P = .005), potentially contributing to diagnostic delay. Taken together, the findings suggest no clinically meaningful benefit for about 5 years of CEE plus MPA use on colorectal cancer outcome.


  • The Legacy Effect of Intensive versus Standard BP Control on the Incidence of Needing Dialysis or Kidney Transplantation

    by Nicholas M. Pajewski, Srinivasan Beddhu, Adam P. Bress, Tara I. Chang, Glenn M. Chertow, Alfred K. Cheung, William C. Cushman, Barry I. Freedman, Tom Greene, Karen C. Johnson, et al.

    Key Points: In the Systolic Blood Pressure Intervention Trial (SPRINT), the longer-term incidence of needing dialysis or transplantation was low and primarily associated with baseline kidney function. Rates of dialysis or transplantation were higher with intensive versus standard treatment, though the differences were not statistically significant. Background: The Systolic Blood Pressure Intervention Trial (SPRINT) showed that intensive lowering of systolic BP increased the risk of incident CKD and episodes of AKI. Whether intensive treatment changes the risk of kidney failure is unknown. The goal of this study was to estimate the legacy effect of intensive versus standard systolic BP lowering on the longer-term incidence of kidney failure. Methods: This study is a secondary analysis of a randomized, open-label clinical trial with observational follow-up. Between 2010 and 2013, patients 50 years and older with hypertension and higher cardiovascular risk excluding those with diabetes mellitus, history of stroke, proteinuria >1 g/d, or polycystic kidney disease were recruited from 102 clinic sites in the United States and Puerto Rico. Participants were randomized to a systolic BP goal of 2 at baseline. Intensive treatment did not significantly increase the risk of kidney failure either overall (cause-specific hazard ratio, 1.20; 95% confidence interval, 0.81 to 1.78) or in the subgroup of participants with baseline eGFR 2 (cause-specific hazard ratio, 1.43; 95% confidence interval, 0.89 to 2.30). Conclusions: Overall, and in patients with eGFR 2, there were higher rates of dialysis or transplantation among SPRINT participants randomized to intensive treatment, but the modest differences observed were not statistically significant. Clinical Trial registry name and registration number: SPRINT, NCT01206062.


  • Open Access

    LONG-TERM ASSOCIATION OF AN INTENSIVE LIFESTYLE INTERVENTION ON FRAILTY AND MULTIMORBIDITY

    by Felicia Simpson, Mark Espeland, Joni Evans, Karen Johnson, Judy Bahnson, Denise Houston, Mia Yang, Lynne Wagenknecht

    Multidomain lifestyle interventions may slow aging as captured by deficit accumulation frailty indices (FIs) and multimorbidity. We previously reported that the 10-year Look AHEAD multidomain intensive lifestyle intervention (ILI) that focused on caloric restriction, increased physical activity, improved diet, and cardiometabolic risk factor monitoring, significantly slowed the progression of both FI and a multimorbidity index during intervention delivery. We assessed whether these benefits endured after ILI delivery was terminated and the degree to which these benefits may be interrelated. The Look AHEAD Aging study enrolled N=1606 individuals, ages 63-94 years, who had been assigned a median of 20 years earlier (i.e., 10 years after ILI was terminated) to either the Look AHEAD ILI or its control condition of diabetes support and education (DSE). At the original Look AHEAD randomization, they had a mean (SD) 39-component FI score of 0.128 (0.056) and mean (SD) 9-component multimorbidity index of 1.63 (1.01), both balanced across intervention groups. When enrolled in the Look AHEAD Aging study, participants who had been assigned to ILI, compared with those assigned to DSE, averaged 6% lower FI scores (p<0.0001). They had also accrued 0.14 fewer additional age-related chronic diseases from baseline (p<0.0001). Relative benefits associated with ILI for these indices were similar for both genders and across the full cohort’s age range. Increases in FI and multimorbidity were highly correlated (r=0.55; p<0.001), similarly in both arms. Multidomain lifestyle interventions can result in persistent long-term benefits in two common markers of aging.

  • Open Access

    The long-term effect of intentional weight loss on changes in bone mineral density in persons with type 2 diabetes: results from the Look AHEAD randomized trial

    by Karen C. Johnson, Andrea Anderson, Kristen M. Beavers, Carolyn J. Crandall, Helen P. Hazuda, Cora E. Lewis, Edward Lipkin, Ann V. Schwartz, F. X. Pi-Sunyer, Qi Zhao, et al.

    Summary: Intentional weight loss has been shown to increase bone loss short term but the long-term effects are not known. Data from the Look AHEAD clinical trial shows that a long term intentional weight loss intervention was associated with greater bone loss at the hip in men. Purpose: Intentional weight loss has been shown to increase bone loss short term and increase frailty fracture risk, but the long-term effects on bone mineral density (BMD) are not known. Methods: Data from a subgroup from the Look AHEAD (LA) multicenter, randomized clinical trial was used to evaluate whether a long term intentional weight loss intervention would increase bone loss. In a preplanned substudy, BMD was assessed at 5 of the 16 LA clinical centers using dual-energy X-ray absorptiometry at baseline, year 8, and the observational visit 12.6–16.3 years after randomization (year 12–16). Results: At year 8, bone density loss (%) was greater in the Intensive Lifestyle Intervention (ILI) group compared with the control group (DSE) for the femoral neck (p = 0.0122) but this finding was not observed at the year 12–16 visit. In analyses stratified by gender, bone density loss (%) was greater at the total hip for men in the ILI group than the DSE group at both the year 8 and year 12–16 visits (year 8 p = 0.0263 and year 12–16 p = 0.0062). This finding was not observed among women. Conclusion: Long term intentional weight loss was associated with greater bone loss at the hip in men. These results taken with the previously published Look AHEAD data from the entire clinical trial showing increased frailty fracture risk with weight loss in the ILI group suggest that when intentional weight loss is planned, consideration of bone density preservation and fracture prevention strategies is warranted. Trial Registration: Clinicaltrials.gov Identifier: NCT00017953. June 21, 2001


  • Open Access

    Healthy Lifestyle Index and Risk of Cardiovascular Disease Among Postmenopausal Women With Normal Body Mass Index

    by Rita Peila, Xiaonan Xue, Qibin Qi, Andrew J. Dannenberg, Matthew A. Allison, Karen C. Johnson, Michael J. LaMonte, Robert A. Wild, Bernhard Haring, Kathy Pan, et al.

    Background: A lifestyle comprising a healthy diet, light alcohol consumption, no smoking, and moderate or intense physical activity has been associated with reduced risk of cardiovascular disease (CVD). We examined the association of a healthy lifestyle index (HLI), derived from scores for each of these components plus waist circumference, with the risk of incident CVD and CVD subtypes in postmenopausal women with normal body mass index (18.5–2 ). Methods and Results: We studied 40 118 participants in the Women's Health Initiative, aged 50 to 79 years at enrollment, with a normal body mass index and no history of CVD. The HLI score was categorized into quintiles. We estimated multivariable adjusted hazard ratios (HR) and 95% CIs for the association of HLI with risk of CVD and CVD subtypes using Cox regression models. A total of 3821 cases of incident CVD were ascertained during a median follow‐up of 20.1 years. Compared with the lowest quintile (unhealthiest lifestyle), higher HLI quintiles showed inverse associations with the risk of CVD (HR quintile−2 =0.74 [95% CI, 0.67–0.81]; HR quintile−3 =0.66 [95% CI, 0.60–0.72]; HR quintile−4 =0.57 [95% CI, 0.51–0.63]; and HR quintile−5 =0.48 [95% CI, 0.43–0.54], P‐trend =63 years), body mass index (</≥ 22.0 kg/m 2 ), and general health status (absence/presence of hypertension, diabetes, or lipid‐lowering drug use) also showed inverse associations between HLI and risk of CVD. Conclusions: Among postmenopausal women with a normal body mass index, adherence to a healthy lifestyle is associated with a reduced risk of clinical CVD and CVD subtypes, underscoring the cardiovascular benefits of maintaining a healthy lifestyle, even for women with a healthy weight.